Inaktiver Wert

Andere Sprachen Signal Genetics Inc Nasdaq

Aktien

US8266401046

Schlusskurs Nasdaq Andere Börsenplätze
- ^USD	-

09.05.	VIRIDIAN THERAPEUTICS, INC. : Bewertung von Oppenheimer kaufen	ZM
09.05.	VIRIDIAN THERAPEUTICS, INC. : Von B. Riley auf neutral herabgestuft	ZM

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

Earnings Flash (VRDN) VIRIDIAN THERAPEUTICS Reports Q1 Revenue $72,000	08.05.
Viridian Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	08.05.
Viridian Therapeutics Highlights Recent Progress and Reports First Quarter 2024 Financial Results	08.05.
Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(4)	06.05.
Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	03.05.
Viridian Therapeutics to Webcast First Quarter 2024 Financial Results on May 8, 2024	29.04.
Foghorn Therapeutics Names Kristian Humer CFO	16.04.
Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	04.04.
VIRIDIAN Kaskela Law LLC Announces Investigation of Viridian Therapeutics, Inc. (VRDN) and Encourages Investors to Contact the Firm	29.03.
Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	06.03.
Viridian Therapeutics to Participate in the Leerink Partners Global Biopharma Conference	05.03.
Viridian Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	27.02.
Viridian Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	27.02.
Earnings Flash (VRDN) VIRIDIAN THERAPEUTICS Posts Q4 Revenue $72,000	27.02.
Viridian Therapeutics Highlights Recent Progress and Reports Fourth Quarter and Full Year 2023 Financial Results	27.02.
Viridian Therapeutics Appoints Jennifer Tousignant as Chief Legal Officer	19.02.
Viridian Therapeutics Names Jennifer Tousignant as Chief Legal Officer	16.02.
Viridian Therapeutics Appoints Jennifer Tousignant as Chief Legal Officer	16.02.
Viridian Therapeutics, Inc. Appoints Jennifer Tousignant as Chief Legal Officer	16.02.
Viridian Therapeutics Announces Inducement Grant under Nasdaq Listing Rule 5635(4)	07.02.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Signal Genetics Inc Nasdaq

Aktien

US8266401046

Andere Sprachen

Filter